Filing Details

Accession Number:
0001487371-16-000192
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-01-25 19:47:00
Reporting Period:
2016-01-21
Filing Date:
2016-01-25
Accepted Time:
2016-01-25 19:47:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1487371 Genmark Diagnostics Inc. GNMK Surgical & Medical Instruments & Apparatus (3841) 272053069
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1134554 Hany Massarany 5964 La Place Court
Carlsbad CA 92008
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-01-21 1,466 $0.00 80,205 No 4 M Direct
Common Stock Disposition 2016-01-21 648 $6.80 79,557 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Market Stock Units Disposition 2016-01-21 1,466 $0.00 1,466 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
46,584 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 406,729 Indirect Massarany Family Trust dated November 15, 2012
Footnotes
  1. The reporting person transferred 818 shares of the Issuer's common stock into the Massarany Family Trust dated November 15, 2012 in connection with the applicable market stock units ("MSUs") vesting event.
  2. The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted MSUs.
  3. Mr. Massarany is the trustee of the Massarany Family Trust and may be deemed to have beneficial ownership of these securities, to the extent of any indirect pecuniary interest in his distributive shares therein.
  4. Each MSU represents the contingent right to receive, following vesting, between 0% and 200% of one share of the Issuer's common stock, subject to the level of achievement of applicable performance conditions. The resulting number of shares acquired upon vesting of the MSUs, if any, is based on the Issuer's total shareholder return for each performance period as compared to the Nasdaq Composite Index.
  5. The MSUs vest in three equal installments, on each of December 31, 2015, December 31, 2016, and December 31, 2017; provided that, at the end of the second and third annual performance periods, the Reporting Person is eligible to receive any shares that were not earned in the first and second annual performance periods to the extent that the Issuer's two-year or three-year total shareholder return, as applicable, exceeds the prior performance results as compared to the Nasdaq Composite Index.